Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent

Proteasome is central to proteostasis network functionality and its over-activation represents a hallmark of advanced tumors; thus, its selective inhibition provides a strategy for the development of novel antitumor therapies. In support, proteasome inhibitors, e.g. Bortezomib or Carfilzomib have de...

Descripción completa

Detalles Bibliográficos
Autores principales: Papanagnou, Eleni-Dimitra, Terpos, Evangelos, Kastritis, Efstathios, Papassideri, Issidora S., Tsitsilonis, Ourania E., Dimopoulos, Meletios A., Trougakos, Ioannis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915155/
https://www.ncbi.nlm.nih.gov/pubmed/29707147
http://dx.doi.org/10.18632/oncotarget.24882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915155/
https://www.ncbi.nlm.nih.gov/pubmed/29707147
http://dx.doi.org/10.18632/oncotarget.24882

Ejemplares similares